ClinicalTrials.gg
CompletedNCT06596135Updated Jul 15, 2026

Open-Label Extension Study of Setmelanotide

A Phase 3 interventional study of Setmelanotide in Obesity Associated With Defects in Leptin-melanocortin Pathway, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 13 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.

Enrollment
9th of 16
28 · median 34
Started
2024
the only one that year
Phase 3
6 of 16
none open now
Registered
14th of 16
by date
Lead sponsor
15 of 16
Rhythm Pharmaceuticals, Inc.

Among the 16 studies testing setmelanotide in Obesity, this one is the 9th largest by enrollment, is the only one that started in 2024, is one of 6 in phase 3, and was the 14th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About setmelanotide

setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing setmelanotide in Obesity, or all of them as a file.
02

Study summary

This is an open-label extension study designed to evaluate the long-term safety and tolerability of continued setmelanotide treatment in male and female patients ≥2 years of age who have completed or transitioned from a previous study with setmelanotide for rare genetic, syndromic, or acquired diseases of obesity upstream of the MC4R pathway.

03

Conditions studied

  • Obesity Associated With Defects in Leptin-melanocortin Pathway

Keywords

  • setmelanotide
  • RM-493
  • obesity
  • melanocortin 4 receptor
  • hypothalamic obesity
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males and females ≥2 years of age who have completed a previous setmelanotide clinical study and who have a condition or indication for which Rhythm plans further clinical development.
  • Agree to use a highly effective form of and follow the study contraception requirements throughout study duration and for 90 days after.
  • Demonstrated clinical benefit in the previous setmelanotide study, as determined by the Investigator.

Key Exclusion Criteria:

  • Any gene variant, syndromic, or acquired disease for which setmelanotide is currently approved in the United States (i.e., patients eligible for commercial setmelanotide (IMCIVREE®).
  • Any new or worsening depression resulting in suicidal thoughts and/or behaviors.
  • Discontinuation from a previous setmelanotide study.
  • History or close family history (parents or siblings) of melanoma.
  • Pregnant and/or breastfeeding women

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Setelanotide (Open-label)

    Once daily (QD) subcutaneous injection of setmelanotide

    Drug: Setmelanotide

Interventions

  • Open-label daily injections of setmelanotide

    Also known as: RM-493, Imcivree

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of setmelanotide assessed by frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 3 years

07

Study locations

13 sites
  • HonorHealth Research Institute
    Scottsdale, Arizona 85258, United States
  • UC San Diego- Rady Children's Hospital
    San Diego, California 92123, United States
  • University of Florida at Gainesville
    Gainesville, Florida 32611, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Children's Minnesota
    Saint Paul, Minnesota 55102, United States
  • University of Buffalo
    Getzville, New York 14068, United States
  • M3 Wake Research, Inc
    Raleigh, North Carolina 27612, United States
  • Geisinger Health System
    Danville, Pennsylvania 17821, United States
  • WR-ClinSearch
    Chattanooga, Tennessee 37421, United States
  • Vanderbilt University School of Medicine
    Nashville, Tennessee 37232, United States
  • Seattle Children's Research Institute
    Seattle, Washington 98105, United States
  • Marshfield Clinical Research Institute
    Marshfield, Wisconsin 54449, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jun 2026, 20 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 20 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2024
First posted
Sep 19, 2024
StartActual
Oct 21, 2024
Primary completionActual
Jun 24, 2026
CompletionActual
Jun 24, 2026
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06596135
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 21, 2024
Primary completion
Jun 24, 2026
Completion
Jun 24, 2026
Last update
Jul 15, 2026

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion